Thermal Enhancement Ratio (TER) in Radiotherapy

• TER is defined as the ratio of radiation doses with and without hyperthermia, serving as a dose-equivalence measure that quantifies radiosensitization.
• It is integrated into the linear–quadratic survival model by scaling the linear (α) and quadratic (β) components, thereby altering the survival curve's shape.
• Mechanistic and thermodynamic models explain TER’s exponential temperature dependence and linear time dependency, guiding optimized hyperthermia–radiotherapy protocols.

Thermal Enhancement Ratio (TER) is a context-dependent enhancement metric whose clearest explicit definition in the literature considered here arises in thermoradiotherapy. In that setting, TER quantifies how much the radiation dose required to reach a fixed biological endpoint is reduced when hyperthermia is applied simultaneously with radiotherapy. The same acronym is not universal across disciplines: in nanofluidics, TER denotes thermoelectric response, while many thermal-transport, astrophysical, and compact-star studies use TER-like ratios or stage-by-stage comparisons without introducing a named TER observable (Mendoza et al., 2020, Rodríguez et al., 19 Jul 2025, Zhang et al., 2023).

1. Formal definition in thermoradiotherapy

In the thermoradiotherapy literature, TER is defined as the ratio of the radiation dose needed to reach the same biological endpoint with radiotherapy alone versus radiotherapy combined with hyperthermia,

$\mathrm{TER}=\frac{D_R}{D_{R+H}},$

where $D_R$ is the dose required with radiation alone and $D_{R+H}$ is the lower dose required when hyperthermia is applied simultaneously. Because hyperthermia sensitizes cells, $D_{R+H}<D_R$, so TER is typically greater than unity (Mendoza et al., 2020).

A closely related formulation writes TER as an explicitly temperature- and time-dependent quantity,

$\mathrm{TER}(T,t)=\frac{D}{D^*}\ge 1,$

where $D$ is the dose needed with radiotherapy alone and $D^*$ is the dose needed when radiotherapy is combined with hyperthermia at temperature $T$ for time $t$. In the same framework, TER can be parameterized as

$$\mathrm{TER}(T,t)=\frac{\alpha^*(T,t)}{\alpha} \qquad\text{or}\qquad \mathrm{TER}(T,t)=\sqrt{\frac{\beta^*(T,t)}{\beta}},$$

with the subsequent analysis choosing the $D_R$0-based formulation (Rodríguez et al., 19 Jul 2025).

This usage makes TER a dose-equivalence variable rather than a direct temperature, power, or transport observable. Its practical meaning is radiosensitization: larger TER implies that the same endpoint can be reached with less radiation.

2. Relation to the linear–quadratic survival formalism

The radiobiological role of TER is most transparent in the linear–quadratic (LQ) survival model. For radiation alone,

$D_R$1

For combined hyperthermia and radiation, the same endpoint is written as

$D_R$2

Substituting $D_R$3 yields

$D_R$4

from which the rescaling relations follow:

$D_R$5

Thus TER steepens both the linear and quadratic components of radiation response, with a stronger effect on $D_R$6 because of the square dependence (Mendoza et al., 2020).

The same rescaling appears in the later mechanistic treatment, where TER is the multiplicative bridge between microscopic DNA-damage processes and macroscopic survival-curve coefficients:

$D_R$7

An immediate consequence is

$D_R$8

so increasing TER lowers $D_R$9, reflecting the increasing importance of sublethal-damage sensitization under combined treatment (Rodríguez et al., 19 Jul 2025).

In this formalism, TER does not merely shift survival curves. It changes the effective initial slope and shoulder structure of the response, thereby encoding both dose reduction and altered repair or damage-accumulation dynamics.

3. Thermodynamic sensitization model

A thermodynamic interpretation of TER models hyperthermia as driving cells from an initial undamaged or alive state $D_{R+H}$0 to a more vulnerable sensitized state $D_{R+H}$1, after which radiation more readily causes irreversible loss of proliferative capacity. In that construction, TER is proportional to the energy invested in sensitization and is written in simplified form as

$D_{R+H}$2

with $D_{R+H}$3 the onset or baseline TER, $D_{R+H}$4 a cell- or tumor-specific sensitivity parameter, $D_{R+H}$5 the heat exposure time, and $D_{R+H}$6 a temperature-dependent sensitization rate. The same idea is also written as

$D_{R+H}$7

with $D_{R+H}$8 in the no-hyperthermia limit (Mendoza et al., 2020).

A central result of that model is the exponential temperature dependence of the sensitization rate,

$D_{R+H}$9

leading to

$D_{R+H}<D_R$0

where $D_{R+H}<D_R$1. Here $D_{R+H}<D_R$2 is the dominant transition temperature, interpreted as the average melting point of the relevant cellular proteins, while $D_{R+H}<D_R$3 and $D_{R+H}<D_R$4 are cell-type-dependent parameters (Mendoza et al., 2020).

The thermodynamic basis is protein denaturation. Using Eyring-type kinetics,

$D_{R+H}<D_R$5

with

$D_{R+H}<D_R$6

and an approximate heat-capacity form

$D_{R+H}<D_R$7

the model recovers the observed exponential TER increase with temperature. The proposed regime is mild hyperthermia, roughly $D_{R+H}<D_R$8, or up to about $D_{R+H}<D_R$9 in some clinical usage, where direct heat killing is minor and sublethal damage accumulation dominates (Mendoza et al., 2020).

This construction treats TER as more than an empirical fit parameter. It becomes a proxy for the fraction of cells that have entered a radiosensitized state due to heat-driven molecular damage.

4. Mechanistic extensions beyond misrepair

A later mechanistic model retains the classical misrepair contribution but adds explicit physical factors that modulate DNA vulnerability under simultaneous hyperthermia and radiotherapy. In that formulation,

$\mathrm{TER}(T,t)=\frac{D}{D^*}\ge 1,$0

where the starred quantities are hyperthermia-modified values. The factors are the ion production rate $\mathrm{TER}(T,t)=\frac{D}{D^*}\ge 1,$1, the number of vulnerable target sites that remain unrepaired $\mathrm{TER}(T,t)=\frac{D}{D^*}\ge 1,$2, the DNA–ion collision cross-section $\mathrm{TER}(T,t)=\frac{D}{D^*}\ge 1,$3, the medium density $\mathrm{TER}(T,t)=\frac{D}{D^*}\ge 1,$4, and the ion diffusion distance $\mathrm{TER}(T,t)=\frac{D}{D^*}\ge 1,$5 (Rodríguez et al., 19 Jul 2025).

The model assigns explicit temperature dependence to each term:

$\mathrm{TER}(T,t)=\frac{D}{D^*}\ge 1,$6

$\mathrm{TER}(T,t)=\frac{D}{D^*}\ge 1,$7

$\mathrm{TER}(T,t)=\frac{D}{D^*}\ge 1,$8

$\mathrm{TER}(T,t)=\frac{D}{D^*}\ge 1,$9

and

$D$0

Keeping the dominant contributions gives the compact analytical form

$D$1

with $D$2 (Rodríguez et al., 19 Jul 2025).

This model concludes that TER increases monotonically with both temperature and time, but much more strongly with temperature. At fixed temperature it rises approximately linearly with treatment time, whereas its temperature dependence is approximately exponential, especially above about $D$3. It also identifies the dominant mechanisms: repair inhibition remains primary, but temperature-dependent amplification of the DNA–ion collision cross-section through DNA breathing or thermal fluctuations is the second most influential contribution. By contrast, medium density changes, diffusion-distance changes, and ion-generation changes are secondary or nearly negligible in the $D$4 range (Rodríguez et al., 19 Jul 2025).

The emphasis on simultaneity is also explicit. The largest TER occurs when hyperthermia and radiotherapy are delivered simultaneously, because fast thermal mechanisms such as DNA breathing act only while radiation-induced damage is being produced.

5. Empirical calibration and observed regimes

The thermodynamic sensitization model was tested against three datasets: CHO cells in vitro, C3H mammary carcinoma xenografts in vivo, and M8013 murine mammary carcinoma cells in vitro. For the CHO and C3H datasets, TER increased approximately linearly with treatment time at fixed temperature, and the temperature dependence of the slope was well fit by the exponential form $D$5. Reported fits were $D$6 for CHO and $D$7 for C3H, with fitted $D$8 values in the mid-to-high $D$9s $D^*$0, consistent with protein melting points from calorimetry studies. For M8013, the model was compared using

$D^*$1

and the agreement improved substantially when only $D^*$2 was used, because the original study reported measurement issues for $D^*$3 (Mendoza et al., 2020).

The later mechanistic model was calibrated against simultaneous hyperthermia-radiotherapy data and against isolated-plasmid experiments by Tomita et al. In the plasmid system, repair inhibition is absent, so the comparison isolates the physical thermal vulnerability of DNA. At $D^*$4, the reported TER at $D^*$5 was $D^*$6 for Tomita’s single-strand-break data, compared with Peyrard–Bishop model values $D^*$7, $D^*$8, and $D^*$9 for three coupling choices. At $T$0, the corresponding values were $T$1 experimentally and $T$2, $T$3, and $T$4 in the model. Cases with stronger coupling, especially case (c), matched the experimental trend better, with deviations of only a few percent near physiological temperature (Rodríguez et al., 19 Jul 2025).

The same mechanistic study also cites prior work showing TER values up to about $T$5 in C3H cells in vivo, depending on temperature and treatment duration. It further argues that temperature control is the dominant lever for radiosensitization, while treatment time matters mainly after repair inhibition is established, with a plateau-like saturation after about $T$6 minutes, especially above $T$7 (Rodríguez et al., 19 Jul 2025).

6. Terminological divergence and TER-like quantities in other fields

A recurring misconception is that TER names a universal thermal-performance ratio. The literature considered here does not support that interpretation. In several areas, no quantity called TER is introduced at all; instead, specific enhancement factors are defined for the physics of that domain.

Domain	TER or TER-like quantity	Usage
Thermoradiotherapy	$T$8, $T$9, $t$0, $t$1	Explicit TER (Mendoza et al., 2020, Rodríguez et al., 19 Jul 2025)
Nanofluidic membranes	TER = thermoelectric response	Characterized by $t$2, $t$3, $t$4, $t$5 (Zhang et al., 2023)
PETE devices	$t$6	Explicit photon-enhancement ratio; no TER (Elahi et al., 2020)
NETEC systems	$t$7	Power-output enhancement; no TER (Ghashami et al., 2017)
Polymer composites	$t$8	Thermal-conductivity enhancement ratio; no named TER (Kumar et al., 2020)
Nanofluids	$t$9	Enhancement ratio for conductivity (Okeke et al., 2012)
Thermoelectric concentrators	$$\mathrm{TER}(T,t)=\frac{\alpha^*(T,t)}{\alpha} \qquad\text{or}\qquad \mathrm{TER}(T,t)=\sqrt{\frac{\beta^*(T,t)}{\beta}},$$0	Relative efficiency gain; no TER (Tan et al., 2024)
Inflationary magnetogenesis	$$\mathrm{TER}(T,t)=\frac{\alpha^*(T,t)}{\alpha} \qquad\text{or}\qquad \mathrm{TER}(T,t)=\sqrt{\frac{\beta^*(T,t)}{\beta}},$$1, $$\mathrm{TER}(T,t)=\frac{\alpha^*(T,t)}{\alpha} \qquad\text{or}\qquad \mathrm{TER}(T,t)=\sqrt{\frac{\beta^*(T,t)}{\beta}},$$2	Thermal enhancement relative to vacuum (Berera et al., 10 Mar 2026)
Protoquark stars	No TER introduced	Thermal history tracked by stage comparisons; closest explicit quantity is rotational mass enhancement (Issifu et al., 20 Jan 2026)

These cases clarify that “thermal enhancement ratio” is not a field-independent primitive. In photon-enhanced thermionic emission, the explicit enhancement metric is the photon-enhancement ratio $$\mathrm{TER}(T,t)=\frac{\alpha^*(T,t)}{\alpha} \qquad\text{or}\qquad \mathrm{TER}(T,t)=\sqrt{\frac{\beta^*(T,t)}{\beta}},$$3, which decreases with increasing solar concentration because photothermal heating raises $$\mathrm{TER}(T,t)=\frac{\alpha^*(T,t)}{\alpha} \qquad\text{or}\qquad \mathrm{TER}(T,t)=\sqrt{\frac{\beta^*(T,t)}{\beta}},$$4 (Elahi et al., 2020). In near-field enhanced thermionic conversion, the closest TER-like quantity is the power ratio $$\mathrm{TER}(T,t)=\frac{\alpha^*(T,t)}{\alpha} \qquad\text{or}\qquad \mathrm{TER}(T,t)=\sqrt{\frac{\beta^*(T,t)}{\beta}},$$5, with reported enhancements of more than $$\mathrm{TER}(T,t)=\frac{\alpha^*(T,t)}{\alpha} \qquad\text{or}\qquad \mathrm{TER}(T,t)=\sqrt{\frac{\beta^*(T,t)}{\beta}},$$6 in one comparison and more than $$\mathrm{TER}(T,t)=\frac{\alpha^*(T,t)}{\alpha} \qquad\text{or}\qquad \mathrm{TER}(T,t)=\sqrt{\frac{\beta^*(T,t)}{\beta}},$$7-fold across a gap sweep, but the paper does not define TER (Ghashami et al., 2017). In inflationary magnetogenesis, the natural thermal enhancement factor compares thermal and vacuum magnetic energy fractions,

$$\mathrm{TER}(T,t)=\frac{\alpha^*(T,t)}{\alpha} \qquad\text{or}\qquad \mathrm{TER}(T,t)=\sqrt{\frac{\beta^*(T,t)}{\beta}},$$8

and the thermal-state spectrum carries the multiplicative factor

$$\mathrm{TER}(T,t)=\frac{\alpha^*(T,t)}{\alpha} \qquad\text{or}\qquad \mathrm{TER}(T,t)=\sqrt{\frac{\beta^*(T,t)}{\beta}},$$9

yet the paper again does not introduce TER as a standalone named observable (Berera et al., 10 Mar 2026).

The broad implication is that TER is best treated as a local term of art. In radiobiology it is a dose-equivalence measure with mechanistic content; elsewhere it may denote thermoelectric response or may be absent entirely, replaced by domain-specific enhancement ratios tied to current, conductivity, efficiency, magnetic energy density, or stellar-structure changes.